CL2014000623A1 - Forma de dosificacion oral que comprende una dispersion del compuesto (2-(1s)-1-(3-etoxi-4-metoxi-fenil)-2-metanosulfonil-etil)-3-oxo-2,3-dihidro-1h-isoindol-4-il)-amida del acido ciclopropanocarboxilico y su uso en el tratamiento y prevencion del cancer, dolor, degeneracion macular, entre otras enfermedades. - Google Patents
Forma de dosificacion oral que comprende una dispersion del compuesto (2-(1s)-1-(3-etoxi-4-metoxi-fenil)-2-metanosulfonil-etil)-3-oxo-2,3-dihidro-1h-isoindol-4-il)-amida del acido ciclopropanocarboxilico y su uso en el tratamiento y prevencion del cancer, dolor, degeneracion macular, entre otras enfermedades.Info
- Publication number
- CL2014000623A1 CL2014000623A1 CL2014000623A CL2014000623A CL2014000623A1 CL 2014000623 A1 CL2014000623 A1 CL 2014000623A1 CL 2014000623 A CL2014000623 A CL 2014000623A CL 2014000623 A CL2014000623 A CL 2014000623A CL 2014000623 A1 CL2014000623 A1 CL 2014000623A1
- Authority
- CL
- Chile
- Prior art keywords
- isoindol
- methanesulfonyl
- dihydro
- oxo
- ethoxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Dispersion Chemistry (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161534841P | 2011-09-14 | 2011-09-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014000623A1 true CL2014000623A1 (es) | 2014-11-07 |
Family
ID=46964044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014000623A CL2014000623A1 (es) | 2011-09-14 | 2014-03-14 | Forma de dosificacion oral que comprende una dispersion del compuesto (2-(1s)-1-(3-etoxi-4-metoxi-fenil)-2-metanosulfonil-etil)-3-oxo-2,3-dihidro-1h-isoindol-4-il)-amida del acido ciclopropanocarboxilico y su uso en el tratamiento y prevencion del cancer, dolor, degeneracion macular, entre otras enfermedades. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9884042B2 (es) |
| EP (1) | EP2765993B1 (es) |
| JP (3) | JP2014526508A (es) |
| KR (1) | KR20140063808A (es) |
| CN (1) | CN105142615A (es) |
| AU (1) | AU2012308663B2 (es) |
| CA (1) | CA2848493A1 (es) |
| CL (1) | CL2014000623A1 (es) |
| ES (1) | ES2803524T3 (es) |
| HK (1) | HK1200356A1 (es) |
| IL (1) | IL231462A0 (es) |
| MX (1) | MX356105B (es) |
| RU (2) | RU2627471C2 (es) |
| SG (1) | SG11201400632YA (es) |
| WO (1) | WO2013040120A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105142615A (zh) | 2011-09-14 | 2015-12-09 | 细胞基因公司 | 环丙烷羧酸{2-[(1s)-1-(3-乙氧基-4-甲氧基-苯基)-2-甲烷磺酰基-乙基]-3-氧代-2,3-二氢-1h-异吲哚-4-基}-酰胺的制剂细胞基因公司公司设立的州：特拉华州 |
| EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
| US20150182457A1 (en) * | 2013-12-31 | 2015-07-02 | Ascendia Pharmaceuticals, Llc | Pharmaceutical Compositions For Poorly Water-Soluble Compounds |
| WO2015175505A1 (en) * | 2014-05-15 | 2015-11-19 | Lundbeck Llc | Tetrabenazine modified release formulation |
| US20170087129A1 (en) * | 2014-05-16 | 2017-03-30 | Celgene Corporation | Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators |
| KR101722564B1 (ko) * | 2014-09-16 | 2017-04-03 | 강원대학교산학협력단 | 수-난용성 약물을 포함하는 고체분산체 |
| US20180185414A1 (en) * | 2015-06-12 | 2018-07-05 | Nissan Chemical Industries, Ltd. | Calcium salt composition and filaggrin production promoter using the same |
| KR20200043618A (ko) * | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995003009A1 (en) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
| WO1995003807A1 (en) | 1993-07-27 | 1995-02-09 | The University Of Sydney | Treatment of age-related macular degeneration |
| US5801195A (en) * | 1994-12-30 | 1998-09-01 | Celgene Corporation | Immunotherapeutic aryl amides |
| IT1274549B (it) | 1995-05-23 | 1997-07-17 | Indena Spa | Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno |
| US5800819A (en) | 1996-01-25 | 1998-09-01 | National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology | Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| ES2339425T3 (es) | 1996-07-24 | 2010-05-20 | Celgene Corporation | 2-(2,6-dioxopiperidin-3-il)-ftalimidas y -1-oxoisoindolinas sustituidas y procedimiento para reducir los niveles de tnf-alfa. |
| HN1998000115A (es) * | 1997-08-21 | 1999-06-02 | Warner Lambert Co | Formas de dosificación farmacéuticas sólidas |
| US6015803A (en) | 1998-05-04 | 2000-01-18 | Wirostko; Emil | Antibiotic treatment of age-related macular degeneration |
| US6225348B1 (en) | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
| US6001368A (en) | 1998-09-03 | 1999-12-14 | Protein Technologies International, Inc. | Method for inhibiting or reducing the risk of macular degeneration |
| US6667316B1 (en) * | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
| US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
| CN1511420A (zh) | 2001-11-09 | 2004-07-07 | 松下电器产业株式会社 | 运动图像编码方法和装置 |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US20100129363A1 (en) | 2002-05-17 | 2010-05-27 | Zeldis Jerome B | Methods and compositions using pde4 inhibitors for the treatment and management of cancers |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US20050203142A1 (en) | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| US20050100529A1 (en) | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| EP1694328A4 (en) | 2003-12-02 | 2010-02-17 | Celgene Corp | METHOD AND COMPOSITIONS FOR THE TREATMENT AND SUPPLY OF HEMOGLOBINOPATHY AND ANEMIA |
| US20050143344A1 (en) | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
| EP2505200A1 (en) | 2004-03-22 | 2012-10-03 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of scleroderma |
| US20050222209A1 (en) | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
| BRPI0510110A (pt) | 2004-04-23 | 2007-09-25 | Celgene Corp | método para tratar, prevenir ou controlar hipertensão pulmonar, e, composição farmacêutica |
| CA2598204C (en) * | 2004-11-09 | 2015-01-13 | Board Of Regents, The University Of Texas System | Stabilized hme composition with small drug particles |
| AU2005304420A1 (en) | 2004-11-12 | 2006-05-18 | Celgene Corporation | Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases |
| MX2007006063A (es) | 2004-11-23 | 2007-07-11 | Celgene Corp | Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de lesion al sistema nervioso central. |
| ES2485316T3 (es) | 2005-09-01 | 2014-08-13 | Celgene Corporation | Usos inmunológicos de compuestos inmunomoduladores para vacunas y terapia anti-enfermedades infecciosas |
| CN101702878B (zh) | 2007-05-11 | 2012-11-28 | 弗·哈夫曼-拉罗切有限公司 | 可溶性差的药物的药物组合物 |
| JP4989733B2 (ja) * | 2008-02-13 | 2012-08-01 | 大日本住友製薬株式会社 | 口腔内崩壊錠 |
| CN102036663A (zh) * | 2008-03-24 | 2011-04-27 | 细胞基因公司 | 用环丙基-n-{2-[(1s)-1-(3-乙氧基-4-甲氧基苯基)-2-(甲磺酰基)乙基]-3-氧代异吲哚啉-4基}甲酰胺治疗银屑病或者银屑病关节炎 |
| JP2012501967A (ja) * | 2008-08-20 | 2012-01-26 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 調節放出型多粒子のホットメルト押出成形 |
| JP5513508B2 (ja) | 2008-09-10 | 2014-06-04 | セルジーン コーポレイション | アミノスルホン化合物を調製するためのプロセス |
| MY160002A (en) | 2009-02-10 | 2017-02-15 | Celgene Corp | Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis |
| ES2727733T3 (es) * | 2009-11-10 | 2019-10-18 | Celgene Corp | Nanosuspensión de un fármaco poco soluble preparada por el proceso de microfluidización |
| ES2739888T3 (es) | 2009-11-30 | 2020-02-04 | Adare Pharmaceuticals Inc | Composiciones y comprimidos farmacéuticos con recubrimiento compresible y métodos de fabricación |
| ES2632979T3 (es) | 2011-01-10 | 2017-09-18 | Celgene Corporation | Formas de dosificación oral de {2-[(1S)-1-(3-etoxi-4-metoxi-fenil)-2-metanosulfonil-etil]-3-oxo-2,3-dihidro-1H-isoindol-4-il}-amida de ácido ciclopropanocarboxílico |
| CN105142615A (zh) | 2011-09-14 | 2015-12-09 | 细胞基因公司 | 环丙烷羧酸{2-[(1s)-1-(3-乙氧基-4-甲氧基-苯基)-2-甲烷磺酰基-乙基]-3-氧代-2,3-二氢-1h-异吲哚-4-基}-酰胺的制剂细胞基因公司公司设立的州：特拉华州 |
| PT2797581T (pt) | 2011-12-27 | 2020-06-18 | Amgen Europe Gmbh | Formulações de (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metanossulfonil-etil]-4-acetilaminoisoindolino-1,3-diona |
-
2012
- 2012-09-13 CN CN201280055703.3A patent/CN105142615A/zh active Pending
- 2012-09-13 MX MX2014003261A patent/MX356105B/es active IP Right Grant
- 2012-09-13 EP EP12766778.0A patent/EP2765993B1/en active Active
- 2012-09-13 KR KR1020147009799A patent/KR20140063808A/ko not_active Application Discontinuation
- 2012-09-13 ES ES12766778T patent/ES2803524T3/es active Active
- 2012-09-13 RU RU2014114499A patent/RU2627471C2/ru active
- 2012-09-13 WO PCT/US2012/054990 patent/WO2013040120A1/en active Application Filing
- 2012-09-13 CA CA2848493A patent/CA2848493A1/en not_active Abandoned
- 2012-09-13 SG SG11201400632YA patent/SG11201400632YA/en unknown
- 2012-09-13 US US14/344,870 patent/US9884042B2/en active Active
- 2012-09-13 AU AU2012308663A patent/AU2012308663B2/en active Active
- 2012-09-13 JP JP2014530765A patent/JP2014526508A/ja not_active Ceased
- 2012-09-13 RU RU2017121896A patent/RU2017121896A/ru unknown
-
2014
- 2014-03-11 IL IL231462A patent/IL231462A0/en unknown
- 2014-03-14 CL CL2014000623A patent/CL2014000623A1/es unknown
-
2015
- 2015-01-29 HK HK15101024.1A patent/HK1200356A1/xx unknown
-
2017
- 2017-02-01 JP JP2017016400A patent/JP6339251B2/ja active Active
- 2017-05-26 JP JP2017104141A patent/JP2017178961A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2014114499A (ru) | 2015-10-20 |
| RU2017121896A (ru) | 2019-01-29 |
| CN105142615A (zh) | 2015-12-09 |
| RU2627471C2 (ru) | 2017-08-08 |
| US20150190374A1 (en) | 2015-07-09 |
| MX356105B (es) | 2018-05-14 |
| JP2014526508A (ja) | 2014-10-06 |
| CA2848493A1 (en) | 2013-03-21 |
| MX2014003261A (es) | 2014-04-10 |
| EP2765993A1 (en) | 2014-08-20 |
| EP2765993B1 (en) | 2020-05-20 |
| AU2012308663B2 (en) | 2017-06-08 |
| KR20140063808A (ko) | 2014-05-27 |
| SG11201400632YA (en) | 2014-04-28 |
| JP2017178961A (ja) | 2017-10-05 |
| JP2017105804A (ja) | 2017-06-15 |
| WO2013040120A1 (en) | 2013-03-21 |
| US9884042B2 (en) | 2018-02-06 |
| IL231462A0 (en) | 2014-04-30 |
| AU2012308663A1 (en) | 2014-04-03 |
| ES2803524T3 (es) | 2021-01-27 |
| HK1200356A1 (en) | 2015-08-07 |
| JP6339251B2 (ja) | 2018-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014000623A1 (es) | Forma de dosificacion oral que comprende una dispersion del compuesto (2-(1s)-1-(3-etoxi-4-metoxi-fenil)-2-metanosulfonil-etil)-3-oxo-2,3-dihidro-1h-isoindol-4-il)-amida del acido ciclopropanocarboxilico y su uso en el tratamiento y prevencion del cancer, dolor, degeneracion macular, entre otras enfermedades. | |
| CL2016002132A1 (es) | Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo. | |
| IL231536A (en) | Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases | |
| CL2014002757A1 (es) | Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer. | |
| CL2015003117A1 (es) | Modificaciones en la estructura cristalina | |
| CL2015001731A1 (es) | Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras. | |
| IT1400982B1 (it) | Collirio osmotico trans-epiteliale per la cura del cheratocono. | |
| IL223783B (en) | Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine | |
| CL2016001424A1 (es) | Composiciones de liberación retardada de lionaclotida | |
| IL271352B (en) | A pharmaceutical preparation containing a derivative of glutarimide and its use in the treatment of eosinophilic diseases | |
| CL2014001792A1 (es) | Compuestos derivados de carbamato; composicion farmaceutica, y uso de los mismos en el tratamiento del dolor, cancer por tumor solido, obesidad, entre otras enfermedades. | |
| CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
| PE20140255A1 (es) | Tableta dispersable en forma oral | |
| JP2014530840A5 (es) | ||
| CO6801754A2 (es) | Una composición farmacéutica para tratar una enfermedad en la cavidad oral que comprende rebamipida | |
| CL2013003229A1 (es) | Compuestos inhibidores del virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vhc. | |
| CL2014001337A1 (es) | Formulacion farmaceutica oral solida que comprende una dispersion solida que comprende a su vez un compuesto especifico derivado de 4-(1-isopropil-1h-pirazol-4-il)-pirimidina y su uso en el tratamiento de una enfermedad proliferativa. | |
| CL2013002905A1 (es) | Composición farmacéutica que comprende fimasartan, una sal, solvato o hidrato del mismo y amlodipina, un isómero, sal, solvato o hidrato del mismo; uso en el tratamiento de hipertensión y enfermedades cardiovasculares. | |
| EP3229824A4 (en) | Oral octreotide administered in combination with other therapeutic agents | |
| PE20130212A1 (es) | Formas polimorficas de st-246 y metodos de preparacion | |
| CL2012003322A1 (es) | Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer. | |
| UY34786A (es) | Procedimiento para la fabricación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo | |
| SG10201704712QA (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
| EP3318879A4 (en) | Gpc3-targeted therapeutic agent administered to patient in whom gpc3-targetd therapeutic ag | |
| UA110979C2 (uk) | Рідка фармацевтична композиція, яка включає нітизинон |